SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Cervical Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Cervical Cancer.

Denosumab Protective Against Diabetes?

Continued treatment with the osteoporosis drug denosumab (Prolia) was tied to a lower risk of developing diabetes in a Taiwanese cohort study. In a propensity

February 14, 2024

How does oxidative stress during pregnancy influence the child’s behavior and emotional states?

Researchers investigate the association between maternal oxidative stress during pregnancy and early childhood mental disorders.

October 19, 2023

Do the benefits of dog ownership on cardiovascular disease and diabetes extend to US military Veterans?

A study finds that dog ownership reduces the risk of cardiometabolic disease among US military veterans.

July 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.